ZAI LAB LTD-ADR (ZLAB) Stock Price, Quote, News and Overview
NASDAQ:ZLAB - Nasdaq - US98887Q1040 - ADR - Currency: USD
ZLAB Quote, Performance and Key Statistics
28.84
-0.09 (-0.33%)
The current stock price of ZLAB is 28.84 USD. In the past month the price decreased by -22.74%. In the past year, price increased by 104.98%.
ZLAB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 320.54 | 36.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About ZLAB
Company Profile
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The firm has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Company Info
ZAI LAB LTD-ADR
Building 1, 4/F, Jinchuang Plaza, 4560 Jinke Road, Pudong
Shanghai SHANGHAI 201210 CN
CEO: Samantha (Ying) Du
Employees: 2175
Company Website: https://www.zailaboratory.com/
Investor Relations: https://ir.zailaboratory.com/
Phone: 862161632588
ZAI LAB LTD-ADR / ZLAB FAQ
What is the stock price of ZAI LAB LTD-ADR today?
The current stock price of ZLAB is 28.84 USD. The price decreased by -0.33% in the last trading session.
What is the ticker symbol for ZAI LAB LTD-ADR stock?
The exchange symbol of ZAI LAB LTD-ADR is ZLAB and it is listed on the Nasdaq exchange.
On which exchange is ZLAB stock listed?
ZLAB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZAI LAB LTD-ADR stock?
13 analysts have analysed ZLAB and the average price target is 38.18 USD. This implies a price increase of 32.37% is expected in the next year compared to the current price of 28.84. Check the ZAI LAB LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZAI LAB LTD-ADR worth?
ZAI LAB LTD-ADR (ZLAB) has a market capitalization of 3.16B USD. This makes ZLAB a Mid Cap stock.
How many employees does ZAI LAB LTD-ADR have?
ZAI LAB LTD-ADR (ZLAB) currently has 2175 employees.
What are the support and resistance levels for ZAI LAB LTD-ADR (ZLAB) stock?
ZAI LAB LTD-ADR (ZLAB) has a support level at 25.3 and a resistance level at 29.95. Check the full technical report for a detailed analysis of ZLAB support and resistance levels.
Is ZAI LAB LTD-ADR (ZLAB) expected to grow?
The Revenue of ZAI LAB LTD-ADR (ZLAB) is expected to grow by 46.81% in the next year. Check the estimates tab for more information on the ZLAB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ZAI LAB LTD-ADR (ZLAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZLAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZLAB, evaluating the profitability, health, valuation and growth aspects
- ZAI LAB LTD-ADR (ZLAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZAI LAB LTD-ADR (ZLAB) Sales and EPS estimates to see what analysts future expectations are.
- ZAI LAB LTD-ADR (ZLAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZAI LAB LTD-ADR (ZLAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZAI LAB LTD-ADR (ZLAB) Stock Chart to make your own analysis
- ZAI LAB LTD-ADR (ZLAB) Latest news and press-releases to stay up to date.
Does ZAI LAB LTD-ADR (ZLAB) stock pay dividends?
ZLAB does not pay a dividend.
When does ZAI LAB LTD-ADR (ZLAB) report earnings?
ZAI LAB LTD-ADR (ZLAB) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of ZAI LAB LTD-ADR (ZLAB)?
ZAI LAB LTD-ADR (ZLAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.34).
What is the Short Interest ratio of ZAI LAB LTD-ADR (ZLAB) stock?
The outstanding short interest for ZAI LAB LTD-ADR (ZLAB) is 7.92% of its float. Check the ownership tab for more information on the ZLAB short interest.
ZLAB Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ZLAB. When comparing the yearly performance of all stocks, ZLAB is one of the better performing stocks in the market, outperforming 97.17% of all stocks.
ZLAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZLAB. While ZLAB seems to be doing ok healthwise, there are quite some concerns on its profitability.
ZLAB Financial Highlights
Over the last trailing twelve months ZLAB reported a non-GAAP Earnings per Share(EPS) of -2.34. The EPS increased by 28.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.68% | ||
| ROE | -30.57% | ||
| Debt/Equity | 0.16 |
ZLAB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to ZLAB. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 41.13% and a revenue growth 46.81% for ZLAB